Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Allergan v. Staar Surgical

This article was originally published in The Gray Sheet

Executive Summary

Allergan v. Staar Surgical: Allergan reports June 16 that a jury in the U.S. District Court for the Central District of California has determined that Microtech and Allergan are the "owner and exclusive licensee, respectively" of U.S. patent No. 4,681,102, which covers the "Bartell Shooter" instrument and a method for inserting intraocular lenses into the eye during cataract surgical procedures. Allergan filed suit in November 1992 seeking "injunctive relief and compensatory and treble damages resulting from willful infringement" by Staar, which claimed ownership of the patent ("The Gray Sheet" Nov. 30, 1992, p. 16). The jury found that neither Staar nor Chiron, which has a sublicense to the patent from Staar, has any rights to the Bartell invention. "As a result of this verdict, we intend to vigorously pursue our claims of willful infringement against Staar and Chiron," Allergan says...

You may also be interested in...

Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.

Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts